Ignite Creation Date:
2025-12-24 @ 1:49 PM
Ignite Modification Date:
2026-01-10 @ 10:07 PM
Study NCT ID:
NCT05665595
Status:
COMPLETED
Last Update Posted:
2025-10-15
First Post:
2022-12-16
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-01-19
Start Date Type:
ACTUAL
Primary Completion Date:
2024-03-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-09-26
Completion Date Type:
ACTUAL
First Submit Date:
2022-12-16
First Submit QC Date:
None
Study First Post Date:
2022-12-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-02-07
Results First Submit QC Date:
None
Results First Post Date:
2025-04-06
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-03
Last Update Post Date:
2025-10-15
Last Update Post Date Type:
ESTIMATED